The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Fumihiro Oshita

Department of Thoracic Oncology

Kanagawa Cancer Center

Nakao 1-1-2

Asahi-ku

Japan

[email]@kcch.jp

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Japan. 2003 - 2012
  • Department of Thoracic Oncology, Laboratory for Molecular Diagnostics and Pathology, Kanagawa Cancer Center, Nakao 1-1-2, Japan. 2004

References

  1. Nedaplatin and Irinotecan in Patients with Large-cell Neuroendocrine Carcinoma of the Lung. Kenmotsu, Y., Oshita, F., Sugiura, M., Murakami, S., Kondo, T., Saito, H., Yamada, K. Anticancer Res. (2012) [Pubmed]
  2. Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials. Oshita, F., Honda, T., Murakami, S., Kondo, T., Saito, H., Noda, K., Yamada, K. J. Thorac. Oncol (2011) [Pubmed]
  3. Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer. Oshita, F., Morita, A., Ito, H., Kameda, Y., Tsuchiya, E., Asai, S., Miyagi, Y. Oncol. Rep. (2010) [Pubmed]
  4. Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. Oshita, F., Saito, H., Murakami, S., Kondo, T., Yamada, K. Am. J. Clin. Oncol. (2010) [Pubmed]
  5. Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. Oshita, F., Ohe, M., Honda, T., Murakami, S., Kondo, T., Saito, H., Noda, K., Yamashita, K., Nakayama, Y., Yamada, K. Br. J. Cancer (2010) [Pubmed]
  6. Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status. Oshita, F., Miyagi, Y., Honda, T., Murakami, S., Kondo, T., Saito, H., Noda, K., Yokose, T., Kameda, Y., Sakuma, Y., Obata, M., Yamada, K. J. Exp. Ther. Oncol. (2010) [Pubmed]
  7. Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer. Oshita, F., Yamada, K., Saito, H., Noda, K. Cancer Chemother. Pharmacol. (2008) [Pubmed]
  8. Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer. Oshita, F., Saito, H., Yamada, K. Oncology (2008) [Pubmed]
  9. Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer. Oshita, F., Saito, H., Yamada, K., Noda, K. Am. J. Clin. Oncol. (2007) [Pubmed]
  10. Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors. Oshita, F., Saito, H., Yamada, K. J. Exp. Ther. Oncol. (2007) [Pubmed]
  11. Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer. Oshita, F., Sekiyama, A., Ito, H., Kameda, Y., Miyagi, Y. Oncol. Rep. (2006) [Pubmed]
  12. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Oshita, F., Matsukuma, S., Yoshihara, M., Sakuma, Y., Ohgane, N., Kameda, Y., Saito, H., Yamada, K., Tsuchiya, E., Miyagi, Y. Br. J. Cancer (2006) [Pubmed]
  13. Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer. Oshita, F., Sekiyama, A., Saito, H., Yamada, K., Noda, K., Miyagi, Y. J. Exp. Ther. Oncol. (2006) [Pubmed]
  14. Genomewide cDNA microarray screening of genes related to benefits and toxicities of platinum-based chemotherapy in patients with advanced lung cancer. Oshita, F., Ikehara, M., Sekiyama, A., Hamanaka, N., Saito, H., Yamada, K., Noda, K., Kameda, Y., Miyagi, Y. Am. J. Clin. Oncol. (2005) [Pubmed]
  15. Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Oshita, F., Ito, H., Ikehara, M., Ohgane, N., Hamanaka, N., Nakayama, H., Saito, H., Yamada, K., Noda, K., Mitsuda, A., Kameda, Y. Am. J. Clin. Oncol. (2004) [Pubmed]
  16. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer. Oshita, F., Ikehara, M., Sekiyama, A., Hamanaka, N., Saito, H., Yamada, K., Noda, K., Kameda, Y., Miyagi, Y. J. Exp. Ther. Oncol. (2004) [Pubmed]
  17. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. Oshita, F., Yamada, K., Saito, H., Noda, K., Hamanaka, N., Ikehara, M. J. Exp. Ther. Oncol. (2004) [Pubmed]
  18. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Oshita, F., Yamada, K., Kato, Y., Ikehara, M., Noda, K., Tanaka, G., Nomura, I., Suzuki, R., Saito, H. Cancer Chemother. Pharmacol. (2003) [Pubmed]
 
WikiGenes - Universities